Cervical dystonia is the most common form of focal dystonia characterized by involuntary muscle contractions causing abnormal movements and posturing of the head and neck and is associated with significant pain. Botulinum toxin is considered first-line therapy in the treatment of pain and abnormal head posturing associated with cervical dystonia. There are currently three botulinum toxin type A neurotoxins and one botulinum type B neurotoxin commercially available and US Food and Drug Administration (FDA) labeled for the treatment of cervical dystonia. This review will focus on the efficacy, safety, and therapeutic use of botulinum type A neurotoxins in the treatment of cervical dystonia. We conclude with a discussion of factors influencing toxin selection including therapeutic effect, duration of effect, side effect profile, cost, and physician preference.
CITATION STYLE
Mills, R. R., & Pagan, F. L. (2015). Patient considerations in the treatment of cervical dystonia: Focus on botulinum toxin type A. Patient Preference and Adherence, 9, 725–731. https://doi.org/10.2147/PPA.S75459
Mendeley helps you to discover research relevant for your work.